Source: Annual Congress 2011 - PG12 TB-PAN-NET Multidrug-resistant and extensively drug-resistant tuberculosis: update on clinical management
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
K. Dheda (Capetown, South Africa). XDR-TB in South Africa: from clinical management to public-health action. Annual Congress 2011 - PG12 TB-PAN-NET Multidrug-resistant and extensively drug-resistant tuberculosis: update on clinical management

Member's Comments

No comment yet.

Related content which might interest you: MDR-TB in Eastern Europe: new public health interventions Source: International Congress 2016 – The problem of multidrug-resistant tuberculosis Year: 2016 TB research and innovation in Latin America Source: Eur Respir Rev, 30 (159) 200107; 10.1183/16000617.0107-2020 Year: 2021 XDR-TB and MDR-TB in Europe: still a challenge Source: Annual Congress 2011 - PG12 TB-PAN-NET Multidrug-resistant and extensively drug-resistant tuberculosis: update on clinical management Year: 2011 Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices Source: Eur Respir J 2016; 48: 808-817 Year: 2016 XDR-TB: Indian perspective Source: Eur Respir J 2007; 30: 178-179 Year: 2007 A study of tuberculosis in an expatriate Nepalese community in South-East London Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations Year: 2013 National evidence on the inefficiency of an inpatient model of tuberculosis management in Eastern Europe Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations Year: 2013 Multidrug-resistant and extensively drug resistance tuberculosis has a strong public health and economical impact in the Republic of Moldova Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations Year: 2013 Rifampicin-resistant tuberculosis (RR-TB) in eastern Europe Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 The health economics of treating MDR-TB in the Indian private sector Source: International Congress 2016 – How the increasing complexity of chronic care management challenges ethics and costs in our healthcare system Year: 2016 Is management of MDR-/XDR-TB in Europe adequate? A TBNET survey Source: Annual Congress 2010 - Multidrug-resistant and extensively drug-resistant tuberculosis Year: 2010 Death rates in patients during and after MDR-TB treatment in a semi rural area of South Africa Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Tuberculosis management in Europe Source: Guideline 1999 Year: 1999 A review of the management of MDR-TB in a resource-limited setting in India Source: Annual Congress 2010 - Global tuberculosis control Year: 2010 A follow up Study of TB patients put on DOTS from South India Source: International Congress 2017 – Clinical challenges in chronic lung diseases Year: 2017 Prevalence and trend of ofloxacin-resistance among MDR-TB including XDR-TB cases in Ukraine Source: International Congress 2015 – Epidemiology of TB: deaths, co-morbidities, migration and children Year: 2015 The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible? Source: Eur Respir J, 50 (2) 1700753; 10.1183/13993003.00753-2017 Year: 2017 Changing prevalence of MDR TB and XDR TB in a tertiary care hospital in India Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management I Year: 2013